Uncovering hepatic transcriptomic and circulating proteomic signatures in MASH: A meta-analysis and machine learning-based biomarker discovery.

Journal: Computers in biology and medicine
PMID:

Abstract

BACKGROUND: Metabolic-associated steatohepatitis (MASH), the progressive form of metabolic-associated steatotic liver disease (MASLD), poses significant risks for liver fibrosis and cardiovascular complications. Despite extensive research, reliable biomarkers for MASH diagnosis and progression remain elusive. This study aimed to identify hepatic transcriptomic and circulating proteomic signatures specific to MASH, and to develop a machine learning-based biomarker discovery model.

Authors

  • Elena Cristina Rusu
    GEMMAIR research Unit (AGAUR) - Applied Medicine (URV). Department of Medicine and Surgery. University Rovira I Virgili (URV), Health Research Institute Pere Virgili (IISPV), 43007, Tarragona, Spain; Institute for Integrative Systems Biology (I2SysBio), University of Valencia and the Spanish National Research Council (CSIC), 46980, Valencia, Spain. Electronic address: elena.cristina.rusu.hutu@gmail.com.
  • Helena Clavero-Mestres
    GEMMAIR research Unit (AGAUR) - Applied Medicine (URV). Department of Medicine and Surgery. University Rovira I Virgili (URV), Health Research Institute Pere Virgili (IISPV), 43007, Tarragona, Spain. Electronic address: helena.clavero@urv.cat.
  • Mario Sánchez-Álvarez
    GEMMAIR research Unit (AGAUR) - Applied Medicine (URV). Department of Medicine and Surgery. University Rovira I Virgili (URV), Health Research Institute Pere Virgili (IISPV), 43007, Tarragona, Spain. Electronic address: mario.sanchez@estudiants.urv.cat.
  • Marina Veciana-Molins
    GEMMAIR research Unit (AGAUR) - Applied Medicine (URV). Department of Medicine and Surgery. University Rovira I Virgili (URV), Health Research Institute Pere Virgili (IISPV), 43007, Tarragona, Spain. Electronic address: mvecianamolins@gmail.com.
  • Laia Bertran
    GEMMAIR research Unit (AGAUR) - Applied Medicine (URV). Department of Medicine and Surgery. University Rovira I Virgili (URV), Health Research Institute Pere Virgili (IISPV), 43007, Tarragona, Spain. Electronic address: lbertranramos@gmail.com.
  • Pablo Monfort-Lanzas
    Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, 6020, Innsbruck, Austria; Institute of Bioinformatics, Biocenter, Medical University of Innsbruck, 6020, Innsbruck, Austria. Electronic address: pablo.monfort@i-med.ac.at.
  • Carmen Aguilar
    Research Group on Metabolic Diseases and Insulin Resistance, Department of Medicine and Surgery, Pere Virgili Institute of Health Research, Rovira i Virgili University, Tarragona, Spain.
  • Javier Camaron
    Internal Medicine Unit, Joan XXIII University Hospital of Tarragona, 43007, Tarragona, Spain. Electronic address: jcamaronm.hj23.ics@gencat.cat.
  • Teresa Auguet
    Research Group on Metabolic Diseases and Insulin Resistance, Department of Medicine and Surgery, Pere Virgili Institute of Health Research, Rovira i Virgili University, Tarragona, Spain.